Weekly Research Analysts’ Ratings Changes for BridgeBio Pharma (BBIO)

BridgeBio Pharma (NASDAQ: BBIO) has recently received a number of price target changes and ratings updates:

• 11/2/2026 – BridgeBio Pharma had its price target raised by Canaccord Genuity Group from $106.00 to $108.00. They now have a “buy” rating on the stock.
• 10/30/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by UBS Group.
• 10/30/2026 – BridgeBio Pharma had its price target lowered by TD Cowen from $110.00 to $100.00. They now have a “buy” rating on the stock.
• 10/30/2026 – BridgeBio Pharma had its price target raised by Morgan Stanley from $87.00 to $88.00. They now have an “overweight” rating on the stock.
• 10/21/2026 – BridgeBio Pharma had its price target lowered by Morgan Stanley from $97.00 to $87.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – BridgeBio Pharma had its price target raised by Piper Sandler from $115.00 to $120.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – BridgeBio Pharma had its price target lowered by Citigroup from $94.00 to $91.00. They now have a “neutral” rating on the stock.
• 10/15/2026 – BridgeBio Pharma is now covered by UBS Group. They set a “buy” rating and a $92.00 price target on the stock.
• 10/14/2026 – BridgeBio Pharma was upgraded by UBS Group to “strong-buy”.
• 10/7/2026 – BridgeBio Pharma had its price target lowered by Barclays from $157.00 to $156.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by Jefferies Financial Group.
• 10/5/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by TD Cowen.
• 10/5/2026 – BridgeBio Pharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/25/2026 – BridgeBio Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.

BridgeBio Pharma Stock Down 1.7%

Shares of NASDAQ BBIO traded down $1.37 during trading hours on Thursday, hitting $78.17. 1,804,089 shares of the stock were exchanged, compared to its average volume of 2,911,446. The company has a market cap of $15.23 billion, a PE ratio of -25.71 and a beta of 0.97. The firm has a fifty day moving average price of $69.92 and a 200-day moving average price of $72.79. BridgeBio Pharma, Inc. has a 12 month low of $62.50 and a 12 month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analyst estimates of $293.47 million. During the same quarter last year, the business earned ($0.95) earnings per share. BridgeBio Pharma’s revenue was up 192.6% on a year-over-year basis. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the sale, the chief accounting officer owned 120,687 shares in the company, valued at approximately $8,792,047.95. This represents a 1.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total value of $690,800.00. Following the completion of the sale, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at $34,241,988.88. The trade was a 1.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 56,980 shares of company stock valued at $4,563,699. Company insiders own 14.23% of the company’s stock.

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.